The impact of guidance on the supply of codeine-containing products on their use in intentional drug overdose

Emma Birchall¹, Ivan J. Perry², Paul Corcoran²,³, Caroline Daly³, Eve Griffin ²,³,*

1 School of Medicine, University College Cork, Cork, Ireland
2 School of Public Health, University College Cork, Cork, Ireland
3 National Suicide Research Foundation, Cork, Ireland

Correspondence: Eve Griffin, School of Public Health, University College Cork, 4.25 Western Gateway Building, Western Road, Cork, T12 XF62, Ireland, Tel: +353 21 420 5718, e-mail: evegriffin@ucc.ie

Introduction

Those who present to hospital with self-harm are at high risk of suicide.¹ The annual incidence rate of hospital-presenting self-harm is ~200 per 100 000, with the most common method involved being intentional drug overdose (IDO), present in between 62% and 84% of all presentations.²⁻⁴ IDO is most common among females and persons aged below 45 years.⁵ Over-the-counter (OTC) medications such as analgesics and opiates are more often consumed in IDOs by young people, whereas prescribed medication, mainly psychotropic drugs such as benzodiazepines, are more common among older people.⁶ Recent studies have found that the incidence of IDOs with OTC medications such as paracetamol and ibuprofen have increased significantly since the 2000s in several countries.⁶⁻⁸⁻¹⁰ Codeine phosphate is a mild-to-moderate opiate analgesic widely used as an OTC pain and cough medication as well as a prescribed medicine.¹⁰ In recent years, codeine misuse has been of increasing concern, with codeine poisonings among the top five substances most frequently referred to the National Poisonings Information Service in the UK.¹¹ A European study estimated that 640 codeine prescriptions are dispensed per 1000 patients,¹² and a survey of codeine use in Ireland found that 6% of people purchase codeine containing products weekly.¹³ Previous research carried out in both the USA and Australia²⁻¹⁶ have determined that suicide and self-harm rates from intentional drug poisonings involving opiates have been steadily increasing since the early 2000s, with one study concluding that codeine containing medications and their availability have significantly contributed to this increase.¹⁶ Opiates have also been increasingly linked with deaths in Ireland and internationally.¹⁷⁻¹⁸ A recent case fatality study of intentional overdose found that opiate drugs were associated with a 12-fold increased risk of death.¹⁹

Restricting access to means is an effective strategy in reducing the incidence of self-harm or suicide.²⁰ Existing research indicates that the frequency of and trends in drugs used in IDOs reflects their availability and prescribing in a population.²¹ Previous research has shown that measures which limit access to certain medications, via restrictions or withdrawals from the market, can be effective in reducing their use in IDO.²²⁻²³

In response to the increasing misuse of codeine in IDO, a number of countries have introduced regulations to restrict the sale of OTC codeine-containing medication.²⁴⁻²⁵ Since 1977, codeine has been listed as a controlled drug in The Misuse of Drugs Act in Ireland.²⁶⁻²⁷ The act currently categorizes drug substances into five schedules, ranging from the most tightly controlled in Schedule 1 to the least tightly controlled in Schedule 5.²⁸ Under this, codeine is classified as a Schedule 5 controlled drug, meaning that it is available OTC in pharmacies, but only under the supervision of a pharmacist. In 2010, the Pharmaceutical Society of Ireland (PSI), in conjunction with the Irish Medical Council, issued guidance for pharmacists which framed this previous legislation in relation to the supply of codeine containing products.²⁹ The guidance identified specific criteria to be adhered to when selling codeine products, including: the storage of codeine-containing products outside of public view, the provision of only short-term prescriptions, the need to advise patients of the correct usage and risks associated with codeine and the requirement that ‘combination’ products are only dispensed as ‘second-line treatment’. The guidelines were published in
May 2010 and inspections of pharmacies commenced from August 2010. The impact of these restrictions and similar ones in other countries has not been extensively evaluated. A recent study examining the impact of the 2010 Irish guidance regarding codeine sales reported a 33% reduction in cases referred to a national poisons information centre following the 2010 guidance.28 In Australia, similar up-scheduling of codeine compound analgesics in 2010 did not impact on an increasing trend in codeine-related poison centre calls, while more recent legislation moving codeine-related medication to prescription only resulted in fewer calls recorded.29 We sought to investigate if the guidance introduced in Ireland in 2010 impacted on the rate of codeine-related IDOs, using national surveillance data on hospital-presenting IDOs.

Methods

Data sources

The National Self-Harm Registry Ireland records information on presentations to every hospital emergency department in the Republic of Ireland (both adult and paediatric) as a result of self-harm. All presentations to hospital involving IDOs recorded by the Registry between 1 January 2007 and 31 December 2013 were included in this study.

The Registry uses the following as its definition of self-harm: ‘an act with non-fatal outcome in which an individual deliberately initiates a non-habitual behaviour that without intervention from others will cause self-harm, or deliberately ingests a substance in excess of the prescribed or generally recognized therapeutic dosage, and which is aimed at realizing changes that the person desires via the actual or expected physical consequences’.30 Data are gathered by trained data registration officers who work independently of the hospitals and follow the Registry’s standardized methods of case ascertainment. The validity of the data and consistency of case ascertainment over time is ensured by regular training of data registration officers, reinforcement of inclusion and exclusion criteria, low staff turnover and annual quality control exercises. More detailed standard operating procedures of the Registry have been previously described.31

The Registry records up to a maximum of five methods per self-harm presentation, using International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10). Intentional drug overdose (IDO) presentations are identified by codes X60–X64. Intentional self-poisoning using other substances (X65–X69) are not included in this study. The names of individual drugs taken in IDO are recorded by the Registry and these names (X60–X64) are not included in this study. The names of individual drugs taken in IDO are recorded by the Registry and these names (X60–X64) are not included in this study. The names of individual drugs taken in IDO are recorded by the Registry and these names (X60–X64) are not included in this study.

Population data from the 2011 national census and annual population estimates for intercensal years (disaggregated by sex and age group) were obtained from the website of the Irish Central Statistics Office (http://www.cso.ie/) and used to calculate event-based rates of codeine-related IDOs.

Study design

In line with the introduction of the guidance, we established a pre-guidance period of 1 January 2007–31 March 2010 and a post-guidance period of 1 October 2010–31 December 2013 in order to determine the impact of the guidance on hospital-presenting IDO. The period 1 April to 30 September 2010 (quarter 2 and 3) was excluded from all analyses, as this was deemed to be the ‘bedding-in’ period for pharmacists to fully implement the new guidelines. The primary outcome measure for this study was the event-based rate per 100 000 of codeine-related IDO. Control measures consisted of the rate of IDOs involving other drugs, as well as IDOs involving non-opioid analgesics and other opiates.

Statistical analyses

The overall incidence of hospital-presenting IDO and codeine-related IDO were calculated based on the number of IDO presentations made to hospital in each calendar year. In the pre-post analysis, quarterly rates per 100 000 population were calculated for all outcome measures. We calculated 95% confidence intervals (CIs) for these rates, using the normal approximation for the Poisson distribution. Rates per 100 000 were also constructed according to gender and age. Initially, changes in the rate of IDOs were examined across five-year age bands. Due to small numbers and following an inspection of the trends in these groups, three larger age groups were used in the final analysis: <25, 25–64 and 65 years and over.

Poisson regression analyses were used to assess the rate changes between the pre- and post-guidance periods and also to calculate the quarterly percentage change (QPC) in rates for each time period, with incidence rate ratios (IRRs) and their 95% CIs being reported. Separate models were constructed to examine changes according to gender and age.

The IRR values, together with the observed number of presentations, were used to estimate the expected and the excess number of codeine-related IDOs that occurred in the post-guidance period, compared with the pre-guidance period. The number of expected presentations was calculated by dividing the obtained IRR by the observed number of presentations in this post-guidance period. The excess number of codeine-related IDOs was calculated by multiplying the expected number of IDOs by the IRR value minus one. The 95% CI of the IRR was used to estimate the 95% CI of the excess number of codeine-related IDOs. The latter’s lower confidence limit minus the expected number of paracetamol-related IDOs and the equivalent calculations were made to generate the upper confidence limit of the excess number. Analyses were conducted using Microsoft Excel, SPSS Version 25 and Stata IC Version 12.0.

Ethical approval

Ethical approval for the Registry has been granted by the National Research Ethics Committee of the Faculty of Public Health Medicine and the Cork Research Ethics Committee. This study is reported in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines for observational studies.32

Results

Sample characteristics

Between 1 January 2007 and 31 December 2013, there were a total of 57759 (annual mean (range): 8251 (7456–8757)) presentations to hospital as a result of IDO, representing 70.4% of all presentations due to self-harm. The majority of these presentations were by females (n = 33 738; 56.8%) and those aged between 25 and 44 years (n = 35 198; 60.9%). Opiates were involved in 12.9% (n = 7434) of all IDOs. At least one codeine-containing medication was recorded in 8.3% (4789) of these. The annual mean number of codeine-related IDOs was 684 (range: 545–774).

Rates of IDO

The total, male and female rates of hospital-presenting IDO were 183.7 (95% CI: 182.3 to 185.3), 153.8 (95% CI: 151.9 to 155.8) and 213.3 (95% CI: 211.0 to 215.6) per 100 000, respectively. The female rate was significantly higher than the male rate (IRR: 1.39; 95% CI: 1.36 to 1.41). The total, male and female rates of codeine-related IDOs for the same period were 15.3 (95% CI: 14.7 to 15.5), 9.9 (95% CI: 9.5 to 10.5) and 20.4 (95% CI: 19.5 to 20.9) per 100 000, respectively. Similar to all IDOs, the female codeine-related IDO rate was significantly higher than the male rate (IRR: 2.03; 95% CI: 1.91 to 2.15).
Figure 1 illustrates the quarterly rates of codeine-related IDO and IDOs involving other drugs across the study period. Considering all IDOs, the rate in 2013 was 11% lower than the rate in 2007 (IRR: 0.89; 95% CI: 0.86 to 0.92). For codeine-related IDO, the rate in 2013 was 25% lower (95% CI: 0.75, 0.67 to 0.83). Between January 2007 and March 2010 (pre-guidance period), there was no significant trend observed in codeine-related IDOs (QPC: ±0.1%, 95% CI: ±0.9 to ±1.2) or those involving other drugs (QPC: ±0.1%, ±0.4 to ±0.3). A pronounced decrease was observed between April 2010 and April 2011 in codeine-related IDOs, where the rate decreased from 17.4 to 12.9 per 100 000. In the second half of the study period, between October 2010 and December 2013, a decreasing trend in the rate of codeine-related IDOs was detected (QPC: −2.0%, −3.1 to −0.8). A similar trend was observed in the same period for rates of IDOs involving other drugs (QPC: −1.5%, −1.8 to −1.1).

Change in codeine-related IDO after introduction of guidance

Considering the pre- and post-guidance periods of January 2007 to March 2010 (pre) and October 2010 to December 2013 (post), the rate of codeine-related IDO was 20% lower in the post-guidance period (IRR: 0.80; 95% CI: 0.75 to 0.85), translating to 509 fewer presentations than expected (624, 387) (tables 1 and 2). The rate of IDOs involving other drugs was also lower in the post-guidance period, although the reductions were much less pronounced than expected (−2% to −6% per year) in those aged under 25 years, −14% in those aged 25–64 years (0.86, 0.80 to 0.92) and −44% (0.56, 0.36 to 0.87) among those aged 65 years and older. The decrease among young people aged below 25 years was similar for males (0.71, 0.59 to 0.87) and females (0.74, 0.65 to 0.83). However, the observed decreases among 25–64 year olds and those aged 65 years and over were significant for females only [25–64 years: 0.80, (0.73 to 0.88) and 65 years and over: 0.48, (0.27 to 0.83)].

Discussion

The aim of this study was to examine the impact of guidance introduced by the Pharmaceutical Society of Ireland in 2010 on the rate of codeine-related IDOs. We found that in the post-guidance period (October 2010 to December 2013), the rate of codeine-related IDOs was 20% lower than the pre-guidance period (January 2007 to March 2010), a total of 509 fewer presentations in the post-guidance period than would be expected. The overall reduction in codeine-related IDOs in the post-guidance period was reflected across all age groups, −23% (0.77, 0.70 to 0.85) in those aged under 25 years, −14% in those aged 25–64 years (0.86, 0.80 to 0.92) and −44% (0.56, 0.36 to 0.87) among those aged 65 years and older. The decrease among young people aged below 25 years was similar for males (0.71, 0.59 to 0.87) and females (0.74, 0.65 to 0.83). However, the observed decreases among 25–64 year olds and those aged 65 years and over were significant for females only [25–64 years: 0.80, (0.73 to 0.88) and 65 years and over: 0.48, (0.27 to 0.83)].
not as pronounced. In addition, a similar decreasing trend in the rate of IDOs involving other drugs in the period following the guidance was also observed.

Our findings are consistent with another Irish study, which reported a 33% reduction in the number of reported codeine poisonings to a national poisoning centre in the year following the introduction of the guidance. Similarly, studies which have examined the impact of guidance regulating codeine use among children have also shown similar decreases. In contrast, an Australian study found that similar re-scheduling did not impact on calls to a national poisoning centre, while a more recent re-scheduling of codeine products to ‘prescription only’ resulted in a significant drop in calls and a decrease in codeine sales. However direct comparisons cannot be made as these calls to poisoning centres do not represent overdoses cases directly, rather more generally concerns regarding medications. While is difficult to identify via observational studies the specific components of these guidelines which led to these reductions, this consultation with a pharmacist which would involve education about the side-effects and the dangers of taking codeine-containing drugs may have been an integral component of the guidance in explaining the impact. Future research could seek to evaluate the effectiveness of specific components of such regulations.

Unlike previous studies, this study further examined the impact of implemented guidance on codeine-related IDOs according to age and gender. While the rates of female codeine-related IDOs were higher overall, the reduction in these presentations was also greater among females, following the introduction of the guidance. While we found that the rate of codeine-related IDOs decreased across all age groups, this reduction was most pronounced for young people aged below 25 years. However, those aged between 25 and 64 years were at highest risk of using a codeine-containing medication in IDOs and perhaps most significantly, accounted for a larger percentage in the post-guidance period (61.5%). This provides evidence to support previous research which also concluded that young to middle-aged people tend to be most likely to self-harm using IDOs. For this reason, they have been identified as a target group for suicide prevention, making research into the effective prevention of self-harm in this group timely and necessary in order to further inform intervention and prevention strategies.

It is challenging to evaluate the impact of regulations such as these due to inherent methodological issues with observational studies—including risk of bias and confounding—as well as a lack of high-quality national data. This is reflected in the relatively small number of published studies from other countries. We used several approaches to strengthen our study. We used national surveillance data from a national self-harm registry, which is one of the few national surveillance systems monitoring the incidence of hospital-presenting self-harm. This approach ensures that all hospital-treated cases of IDO are included in this study and overcomes some of the limitations of poisons information centre data, including difficulties in establishing intent. Furthermore, we used several approaches to validate that the changes observed were linked with the exposure we examined. This included the construction of equal pre- and post-guidance periods, as well as the exclusion of a ‘bedding-in’ period where the guidance was being rolled out and implemented. We also used a number of control measures to compare the changes observed to other IDO presentations and see if there was a substitution effect among medications, of which there was none.

However, there were some limitations to the study. Firstly, hospital-presenting self-harm was examined, and therefore IDOs which were untreated or seen only by a general practitioner were not included in this study. Lastly, there may have been other legislation or social and economic factors impacting the rates of IDOs during this period that were not fully accounted for in this study. In order to accurately estimate the impact of the guidance, we used the rate of other IDOs and those involving non-opioid analgesics and other opiates as control measures for the changes in both time periods. This also served to identify any substitution effects in the types of drugs used. The decrease in rates of IDO involving other drugs was much less pronounced, while rates of IDOs involving other opiates did not change. However it is difficult to be conclusive about whether the patterns observed were as a direct result of the regulations introduced, in particular as a similar decreasing trend in the post-guidance period was observed for IDOs involving other drugs. For example, the pre-guidance period we used included the onset of the global economic recession in 2008, which was associated with increases in both the incidence of self-harm and suicide in Ireland. The highest rates of IDOs involving other drugs and codeine-related IDOs were observed during the first quarter of 2008. However, this previous study did show that the rates of self-harm continued to rise during the period of austerity measures in Ireland following the recession between 2009 and 2012. The lower rates of IDO in this period could be due to an increased use in more lethal methods of self-harm during this time, as has been shown in young people. However, the reduction in codeine-related IDOs was greater than...
for the other drug groups examined, suggesting that the regulations were effective in reducing the use of codeine in IDO.

Legislation limiting the sale of other medications such as reducing paracetamol pack-sizes and the withdrawal of drugs such as distalgesic\(^2\),\(^3\)\(^,\)\(^2\)\(^,\)\(^2\) have also been shown to be effective in reducing the use of these drugs in IDO. This study further adds to this evidence base that universal suicide prevention measures can have positive impacts on those at risk of self-harm and suicide and demonstrates the important role that means restrictions measures have in national and international suicide prevention strategies and policy.\(^2\)\(^,\)\(^3\)\(^,\)\(^2\)\(^,\)\(^2\) This study has indicated that the introduction of guidance by the PSI in May 2010 which restricted the supply of codeine-containing drugs was associated with a significant reduction in codeine-related IDOs in period following its introduction. This study will inform policymakers and future governments on the effectiveness of means restriction interventions to prevent suicidal behaviour.

Acknowledgements

We would like to acknowledge all those involved in the development and operation of the National Self-Harm Registry Ireland.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors. The National Self-Harm Registry Ireland is funded by the Irish Health Service Executive’s National Office for Suicide Prevention.

Conflicts of interest: None declared.

Data availability

To access data from the National Self-Harm Registry Ireland, please contact the National Suicide Research Foundation (info@nsrf.ie).

Key points

- In Ireland, increases in opiate misuse led to guidance introduced in 2010 which restricted the sale of codeine-containing medication.
- This study evaluated the impact of this guidance on hospital-presenting self-harm, using codeine medication.
- The introduction of this guidance was associated with a 20% decrease in codeine-related intentional drug overdoses (IDO)s or 509 presentations, in the following three years.
- Rates of IDO involving other drugs did not change to the same extent, and there was no evidence of a substitution effect.
- This research adds to a growing body of evidence that which demonstrate that public health measures restricting access to potentially harmful substances are an effective suicide prevention strategy.

References

1. Carroll R, Metcalfe C, Gunnell D. Hospital presenting self-harm and risk of fatal and non-fatal repetition: systematic review and meta-analysis. PLoS One 2014;9: e89494.
2. Griffin E, McTernan N, Wrigley C, et al. National Self-Harm Registry Ireland Annual Report 2018. Cork: National Suicide Research Foundation; 2019.
3. Geulayov G, Kapur N, Turnbull P, et al. Epidemiology and trends in non-fatal self-harm in three centres in England, 2000-2012: findings from the Multicentre Study of Self-harm in England. BMJ Open 2016;6:e010538.
4. Vancayseele N, Portzky G, van Heeringen K. Increase in self-injury as a method of self-harm in Belgium: 1987-2013. PLoS One 2016;11:e0156711.
5. Daly C, Griffin E, Ashcroft DM, et al. Frequently used drug types and alcohol involvement in intentional drug overdoses in Ireland: a national registry study. Eur J Public Health 2018;28:681–6.
6. Daly C, Griffin E, Corcoran P, et al. Paracetamol-related intentional drug overdose among young people: a national registry study of characteristics, incidence and trends, 2007-2018. Soc Psychiatry Psychiatr Epidemiol 2021;56:773–81.
7. Gilley M, Sivilotti MLA, Jourlin DN, et al. Trends of intentional drug overdose among youth: a population-based cohort study. Clin Toxicol (Phila) 2020;58:711–5.
8. Cairns R, Brown JA, Wylie CE, et al. Paracetamol poisoning-related hospital admissions and deaths in Australia, 2004-2017. Med J Aust 2019;211:218–23.
9. Hopkins AG, Spiller HA, Kistamari S, et al. Suicide-related over-the-counter analgesic exposures reported to United States poison control centers, 2000-2018. Pharmacoepidemiol Drug Saf 2020;29:1011.
10. Carney T, Wells J, Parry CDH, et al. A comparative analysis of pharmacists’ perspectives on codeine use and misuse - a three country survey. Subst Abuse Treat Prev Policy 2018;13:12.
11. O'Neill D. Misuse and dependence on codeine-containing medicines. Drugnet Ireland 2016;57:16–7.
12. Foley M, Rich E, Norman I, Van Hout M. Codeine Consumption Through Prescribing in the Republic of Ireland, the Republic of South Africa and the United Kingdom. Supplement to the CODEMISUSED Scoping Review 2014; Brussels: CODEMISUSED Project European Commission 7th Framework Programme, EU.
13. Wells JS, Bergin M, Van Hout MC, et al. Purchasing over the counter (OTC) medicinal products containing codeine - easy access, advertising, misuse and perceptions of medicinal risk. J Pharm Pharmacol 2018;71:30049.
14. Hempstead K, Phillips J. Divergence in recent trends in deaths from intentional and unintentional poisoning. Health Aff (Millwood) 2019;38:29–35.
15. Olfson M, Rossen LM, Wall MM, et al. Trends in intentional and unintentional opioid overdose deaths in the United States, 2000-2017. JAMA 2019;322:2340–2.
16. Roxburgh A, Hall WD, Burns L, et al. Trends and characteristics of accidental and intentional codeine overdose deaths in Australia. Med J Aust 2015;203:299.
17. Brett J, Wylie CE, Raubenheimer J, et al. The relative lethal toxicity of pharmaceutical and illicit substances: a 16-year study of the Greater Newcastle Hunter Area, Australia. Br J Clin Pharmacol 2019;85:2098–107.
18. Health Research Board. National Drug-Related Deaths Index 2004 to 2015 data. http://www.drugsandalcohol.ie/28086; 2016 (9 April 2016, date last accessed).
19. Daly C, Griffin E, Corcoran P, et al. A national case fatality study of drugs taken in intentional overdose. Int J Drug Policy 2020;76:102609.
20. Zalsman G, Hawton K, Wasserman D, et al. Suicide prevention strategies revisited: 10-year systematic review. Lancet Psychiatry 2016;3:464–59.
21. Hawton K, Bergen H, Simkin S, et al. Impact of different pack sizes of paracetamol in the United Kingdom and Ireland on intentional overdoses: a comparative study. BMC Public Health 2011;11:460.
22. Corcoran P, Reulbach U, Keeley HS, et al. Use of analgesics in intentional drug overdose presentations to hospital before and after the withdrawal of distalgesic from the Irish market. BMC Clin Pharmacol 2010;10:6.
23. Morthorst BR, Erlangsen A, Chaine M, et al. Restriction of non-opioid analgesics or 509 presentations, in the following three years.
24. Morthorst BR, Erlangsen A, Chaine M, et al. Restriction of non-opioid analgesics or 509 presentations, in the following three years.
25. Morthorst BR, Erlangsen A, Chaine M, et al. Restriction of non-opioid analgesics or 509 presentations, in the following three years.
26. Morthorst BR, Erlangsen A, Chaine M, et al. Restriction of non-opioid analgesics or 509 presentations, in the following three years.
27. Morthorst BR, Erlangsen A, Chaine M, et al. Restriction of non-opioid analgesics or 509 presentations, in the following three years.
28. Morthorst BR, Erlangsen A, Chaine M, et al. Restriction of non-opioid analgesics or 509 presentations, in the following three years.
29. Morthorst BR, Erlangsen A, Chaine M, et al. Restriction of non-opioid analgesics or 509 presentations, in the following three years.
30 Kennedy C, Duggan E, Bennett K, Williams DJ. Rates of reported codeine-related poisonings and codeine prescribing following new national guidance in Ireland. *Pharmacoepidemiol Drug Saf* 2019;28:106–11.

31 Cairns R, Brown JA, Buckley NA. The impact of codeine re-scheduling on misuse: a retrospective review of calls to Australia’s largest poisons centre. *Addiction* 2016;111:1848–53.

32 Cairns R, Schaffer AL, Brown JA, et al. Codeine use and harms in Australia: evaluating the effects of re-scheduling. *Addiction* 2020;115:451–9.

33 Schmidtke A, Bille-Brahe U, DeLeo D, et al. Attempted suicide in Europe: rates, trends and sociodemographic characteristics of suicide attempters during the period 1989–1992. Results of the WHO/EURO Multicentre Study on Parasuicide. *Acta Psychiatr Scand* 1996;93:327–38.

34 Perry II, Corcoran P, Fitzgerald AP, et al. The incidence and repetition of hospital-treated deliberate self harm: findings from the world’s first national registry. *PLoS One* 2012;7:e31663.

35 von Elm E, Altman DG, Egger M, STROBE Initiative, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *BMJ* 2007;335:806–8.

36 Lin CW, Wang CH, Huang WI, et al. Impact of safety-related regulations on codeine use in children: a quasi-experimental study using Taiwan’s National Health Insurance Research Database. *Drug Saf* 2017;40:615–27.

37 Hedenmalm K, Blake K, Donegan K, et al. A European multicentre drug utilisation study of the impact of regulatory measures on prescribing of codeine for pain in children. *Pharmacoepidemiol Drug Saf* 2019;28:1086–96.

38 Craig P, Katikireddi SV, Leyland A, Popham F. Natural experiments: an overview of methods, approaches, and contributions to public health intervention research. *Annu Rev Public Health* 2017;38:39–56.

39 Corcoran P, Griffin E, Arensman E, et al. Impact of the economic recession and subsequent austerity on suicide and self-harm in Ireland: an interrupted time series analysis. *Int J Epidemiol* 2015;44:969–77.

40 Sarchiapone M, Mandelli L, Iosue M, et al. Controlling access to suicide means. *Int J Environ Res Public Health* 2011;8:6550–62.